The FDA has approved ATryn(antithrombin [recombinant], from GTC Biotherapeutics and Ovation Pharmaceuticals), an anticoagulant for the prevention of peri-operative andperi-partum blood clots in patients with hereditary antithrombin (AT)deficiency. ATryn is a therapeutic protein derived fromthe milk of goats that have been genetically engineered by introducing a segmentof DNA into their genes (called a recombinant DNA or rDNA construct) withinstructions for the goat to produce human antithrombin in itsmilk. 

ATryn is expected to be available inthe second quarter of 2009. 

For more information call (866)402-8520 or visit www.ovationpharma.com.